drugset / Trial / NCT05323201
Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
Phase 1/2
Recruiting
15 enrolled
The Affiliated Hospital of Xuzhou Medical University
IIT MediTech Co. Ltd · collabXuzhou Medical University · collab
NaSequentialOpen-labelTreatment
Summary
This is single center, open-label phase I/II, non-randomized study which will enroll patients with recurrent advanced hepatocellular carcinoma to evaluate the safety, feasibility, and efficacy of fully human B7H3 CAR-T in treating hepatocellular carcinoma.
Timeline
- Start
- 2022-02-10
- Primary completion
- 2024-02-10
- Completion
- 2027-02-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | fhB7H3.CAR-Ts | Cell therapy | 0.5 cells/kg | Other |
| Subject | fhB7H3.CAR-Ts | Cell therapy | 1 cells/kg | Other |
| Subject | fhB7H3.CAR-Ts | Cell therapy | 3 cells/kg | Other |
| Subject | fhB7H3.CAR-Ts | Cell therapy | 5 cells/kg | Other |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |